Testing the right tafenoquine dose for malaria prevention
Treatments studied
Part of Infections clinical trials.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptoms from P. vivax malaria only (no other malaria type), confirmed by a blood test
- You have a fever now or had fever within the last 7 days
- Your G6PD level is at least 70% of the typical group average (a blood test will check this)
- You are at least 2 years old and weigh over 10 kg
- You can understand the study and sign written consent (and agree to follow the plan for 4 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This Phase 3 trial tests whether giving malaria medicine to people in high-risk households (a “mass drug administration” campaign) can stop local relapses and eliminate vivax malaria. If you live close to a recent malaria case, you may be offered a preventive dose, based on age and medical safety checks.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This trial tests whether adding the drug tafenoquine to standard malaria treatment can prevent the return of P. vivax malaria. It is for adults who have a normal G6PD enzyme level and are healthy enough to participate.
This study tests new combinations of antimalarial drugs to better cure P. vivax malaria, a type of malaria parasite. You would receive experimental drug combinations and be monitored for about 6 months to see if they work and are safe.
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
Hear when a new Plasmodium Vivax Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.